Afshin Amini
The final results of sufferers with systemic diffuse big B-mobileular lymphoma (DLBCL) had stepped forward over the last decade with the addition of monoclonal antibody remedy. Unfortunately, about five% of those sufferers nonetheless advanced a secondary vital anxious system (CNS) recurrence observed continuously with the aid of using speedy loss of life. This fee is notably expanded in sufferers with positive excessive-threat capabilities. Although prophylaxis in opposition to CNS recurrence with both intrathecal or intravenous methotrexate is generally used for such sufferers, to the authors' expertise, there may be no popular of care. Retrospectively evaluated changed into the position of excessive-dose systemic methotrexate blended with popular cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab (R-CHOP) chemotherapy to lower CNS recurrence in excessive-threat sufferers.
Teile diesen Artikel
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi 